中国P站

Mucosal vaccine; Respiratory infections; Adjuvants; Delivery systems; Chitosan nanoparticles; Oral vaccine; Influenza; RSV; Microbiome; Microneedle patches

Introduction

Mucosal vaccine development is rapidly advancing, with a focus on respiratory infectious diseases [1].

These advancements emphasize novel adjuvants and delivery systems to improve immune responses within the respiratory tract [1].

Chitosan nanoparticles are also showing promise as delivery systems, enhancing antigen uptake and immune cell activation in the gut-associated lymphoid tissue (GALT) [2].

An oral vaccine candidate against influenza is being explored, with preclinical models indicating that it induces both humoral and cellular immune responses in the respiratory mucosa [3].

Live attenuated bacteria are being evaluated as vectors for antigen delivery to mucosal surfaces, with results demonstrating their capacity to elicit strong and long-lasting immunity [4].

Nasal vaccines against respiratory syncytial virus (RSV) are also under development, highlighting their potential to induce protective immunity in the upper respiratory tract and prevent severe lower respiratory tract infections [5].

Plant-based expression systems are being explored for the production of mucosal vaccine antigens, offering a scalable and cost-effective manufacturing approach [6].

Extracellular vesicles (EVs) are being investigated as a novel delivery system for mucosal vaccines, showcasing their ability to transport antigens across the mucosal barrier and induce potent immune responses [7].

Intranasal delivery of subunit vaccines, such as those targeting Streptococcus pneumoniae with chitosan nanoparticles, is showing enhanced antibody responses and reduced bacterial colonization in the nasopharynx [8].

The microbiome's impact on mucosal vaccine efficacy is a critical area of study, suggesting that modulating the gut microbiota can enhance the immune response to oral vaccines [9].

Finally, microneedle patches are being explored for mucosal vaccine delivery, showing enhanced antigen presentation and immune cell activation in the skin-associated lymphoid tissue (SALT) [10].

Description

Mucosal vaccine development is a multifaceted field with diverse approaches to combatting infectious diseases [1]. One prominent strategy involves using novel adjuvants and delivery systems to enhance immune responses specifically within the respiratory tract [1]. For instance, chitosan nanoparticles have shown potential as delivery systems, improving antigen uptake and activating immune cells in the gut-associated lymphoid tissue (GALT) [2]. These targeted approaches aim to elicit robust and localized immunity.

Oral vaccines represent another significant area of focus, with candidates against influenza virus demonstrating promising results in preclinical models [3]. These vaccines induce both humoral and cellular immune responses in the respiratory mucosa, offering a non-invasive method of immunization [3]. Similarly, live attenuated bacteria are being explored as vectors for delivering antigens to mucosal surfaces, showcasing their ability to elicit strong and long-lasting immunity [4]. This approach leverages the body's natural immune pathways.

Nasal vaccines against respiratory syncytial virus (RSV) are also being developed, with the goal of inducing protective immunity in the upper respiratory tract and preventing severe lower respiratory tract infections [5]. Plant-based expression systems offer a scalable and cost-effective method for producing mucosal vaccine antigens [6]. This can significantly reduce manufacturing costs and increase vaccine accessibility.

Novel delivery systems like extracellular vesicles (EVs) are under investigation for their ability to transport antigens across the mucosal barrier and induce potent immune responses [7]. Furthermore, intranasal co-delivery of subunit vaccines, such as those targeting Streptococcus pneumoniae, with chitosan nanoparticles, demonstrates enhanced antibody responses and reduced bacterial colonization [8]. The gut microbiome's role in influencing mucosal vaccine efficacy is also being recognized, highlighting the potential of modulating gut microbiota to enhance immune responses [9]. Finally, microneedle patches are being explored for mucosal vaccine delivery, showing improved antigen presentation and immune cell activation [10].

Conclusion

Recent advancements in mucosal vaccine development are focused on respiratory infectious diseases, emphasizing the use of novel adjuvants and delivery systems to enhance immune responses in the respiratory tract. Chitosan nanoparticles show promise as delivery systems, enhancing antigen uptake and immune cell activation in the gut-associated lymphoid tissue (GALT). An oral vaccine candidate against influenza is being explored, with preclinical models indicating the induction of both humoral and cellular immune responses in the respiratory mucosa. Live attenuated bacteria are being evaluated as vectors for antigen delivery to mucosal surfaces, with results showing their capacity to elicit strong and long-lasting immunity. Nasal vaccines against respiratory syncytial virus (RSV) are also being developed, highlighting their potential to induce protective immunity in the upper respiratory tract and prevent severe lower respiratory tract infections. Plant-based expression systems are being explored for the production of mucosal vaccine antigens, offering a scalable and cost-effective manufacturing approach. Extracellular vesicles (EVs) are under investigation as a novel delivery system for mucosal vaccines, showcasing their ability to transport antigens across the mucosal barrier and induce potent immune responses. Intranasal delivery of subunit vaccines, such as those targeting Streptococcus pneumoniae with chitosan nanoparticles, demonstrates enhanced antibody responses and reduced bacterial colonization in the nasopharynx. The microbiome's impact on mucosal vaccine efficacy is being studied, suggesting that modulating the gut microbiota can enhance the immune response to oral vaccines. Microneedle patches are being explored for mucosal vaccine delivery, showing enhanced antigen presentation and immune cell activation in the skin-associated lymphoid tissue (SALT).

References

1. Sachin DR, Anushka V, Ashley B (2023) .J Control Release 354:781-800.

   , ,

2. Imran IK, Vivek BP, Arun KS (2020) .Sci Rep 10:14709.

   , ,

3. Ji YP, Mi-Kyung K, Yeon-Mi L (2019) .PLoS One 14:e0212724.

   , ,

4. A M, M R, F A (2021) .Vet Immunol Immunopathol 236:110260.

   , ,

5. Amy JS, David MB, Tracy H (2019) .Vaccine 37:3598-3606.

   , ,

6. Armin D, Gholamreza M, Fatemeh G (2021) .Artif Cells Nanomed Biotechnol 49:389-398.

   , ,

7. Ying L, Qing W, Dong JL (2022) .Front Immunol 13:849055.

   , ,

8. Ying Z, Jian W, Jie L (2024) .Int J Biol Macromol 255:128355.

   , ,

9. Sailaja R, Rebecca B, Ki L (2021) .Microbiome 9:255.

   , ,

10. Yu I, Masaki S, Hiroko K (2020) .Pharmaceutics 12:1185.

    , ,